Articles and Resources
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) mesothelioma
The Company now has Three Commercially Available Molecular Diagnostic Tests for Cancer
The Company Expects to Perform Approximately 2,000 Tests During 2009 in
its Laboratory in Philadelphia, PA.
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania,
December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG),
the leading developer of microRNA-based molecular diagnostics, announced
today the introduction of its third diagnostic test, miRview(TM) meso. The
test is now commercially available through Rosetta Genomics CLIA-certified
lab in Philadelphia.
To order the test, physicians may contact 1-888-522-7971, or visit the
company's website http://www.rosettagenomics.com.
"I am very excited to finally see a molecularly-based test that can
objectively differentiate mesothelioma from several types of carcinomas in
the lung with such high level of accuracy" noted Harvey Pass, MD, Division
Chief for Thoracic Surgery and Thoracic Oncology at the New York University
Langone Medical Center. "Ruling out Mesothelioma from lung cancer for
individuals that were exposed to asbestos can be difficult and challenging. I
am sure that this test will become an important tool for both oncologists and
pathologists in obtaining the right diagnosis in these patients."
Malignant pleural mesothelioma is directly linked to exposure to asbestos
particles, as well as to various heavy metals. Rescue workers, shipyard
workers, and miners are at increased risk of developing mesothelioma.
Currently, there is no single diagnostic test that is entirely conclusive for
this differentiation. In addition, pathological diagnosis may suffer from
significant inter-observer variability, and in the absence of a single
specific and reliable test, mesothelioma can be difficult to identify from
miRview(TM) meso differentiates mesothelioma, a cancer connected to
asbestos exposure, from other carcinomas in the lung. Currently, there is no
single diagnostic test that is entirely conclusive for this differentiation.
Each year, approximately 130,000 patients in the United States are diagnosed
with adenocarcinoma of the lung. miRview(TM) meso is available for $3170.
Rosetta Genomics currently has approximately $16M in cash, and it expects
to perform approximately 2,000 tests during 2009 in its laboratory in
The company is now offering the following ground-breaking tests through
its clinical lab in Philadelphia:
- miRview(TM) mets - This test can accurately identify the
primary tumor site in patients presenting with metastatic cancer, as well
in patients with Cancer of Unknown Primary (CUP). In the U.S., hundreds
of thousands of patients are diagnosed each year with metastatic cancer,
and approximately 70,000 patients are labeled CUP patients. miRview(TM)
mets is available for $3650.
- miRview(TM) squamous - This test differentiates between two
subtypes of non small cell lung cancer (NSCLC). This diagnosis is
important as some NSCLC patients have demonstrated varying response
patterns ranging from a high incidence of severe or fatal internal
bleeding in the lungs to overall poor response to treatment. In the US
alone, approximately 170,000 patients are diagnosed each year with NSCLC.
miRview(TM) squamous is available for $3170.
- miRview(TM) meso - This test differentiates mesothelioma, a
cancer connected to asbestos exposure, from other carcinomas in the lung.
Currently, there is no single diagnostic test that is entirely conclusive
for this differentiation. Each year, approximately 130,000 patients in
the United States are diagnosed with adenocarcinoma of the lung.
miRview(TM) meso is available for $3170.
MicroRNAs (miRNAs) are recently discovered, naturally occurring, small
RNAs that act as master regulators and have the potential to form the basis
for a new class of diagnostics and therapeutics. Since many diseases are
caused by the abnormal activity of proteins, the ability to selectively
regulate protein activity through microRNAs could provide the means to treat
a wide range of human diseases. In addition, microRNAs have been shown to
have different expression in various pathological conditions. As a result,
these differences may provide for a novel diagnostic strategy for many
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leading developer of microRNA-based
molecular diagnostics. Founded in 2000, the company's integrative research
platform combining bioinformatics and state-of-the-art laboratory processes
has led to the discovery of hundreds of biologically validated novel human
microRNAs. Building on its strong IP position and proprietary platform
technologies, Rosetta Genomics is working on the application of these
technologies in the development of a full range of microRNA-based diagnostic
tools. The company have their first three microRNA-based tests, miRview(TM)
squamous, miRview(TM) mets, and miRview(TM) meso, commercially available
through its Philadelphia-based CLIA-certified lab.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future
expectations, plans and prospects, including without limitation, statements
relating to the role of microRNAs in human physiology and disease, the
potential of microRNAs in the diagnosis and treatment of disease and the
timing of introduction of additional microRNA-based diagnostic tests,
including miRview meso, miRview squamos and miRview mets, constitute
forward-looking statements for the purposes of the safe harbor provisions
under The Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including risks related
to: Rosetta's approach to discover and develop novel diagnostics and
therapeutic tools, which is unproven and may never lead to commercially
accepted products or services; Rosetta's ability to fund and the results of
further pre-clinical and clinical trials; Rosetta's ability to obtain,
maintain and protect the intellectual property utilized by Rosetta's
products; Rosetta's ability to enforce its patents against infringers and to
defend its patent portfolio against challenges from third parties; Rosetta's
ability to obtain additional funding to support its business activities;
Rosetta's dependence on third parties for development, manufacture,
marketing, sales, and distribution of products; Rosetta's ability to
successfully develop and commercialize its candidate tools, products and
services; Rosetta's ability to obtain regulatory clearances or approvals that
may be required for its products and services; the ability to obtain coverage
and adequate payment from health insurers for the products and services
comprising Rosetta's technology; competition from others using technology
similar to Rosetta's and others developing products for similar uses;
Rosetta's dependence on collaborators; and Rosetta's short operating history;
as well as those risks more fully discussed in the "Risk Factors" section of
Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as
filed with the Securities and Exchange Commission. In addition, any
forward-looking statements represent Rosetta's views only as of the date of
this release and should not be relied upon as representing its views as of
any subsequent date. Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
Contact: Media & Investors, Ron Kamienchick, T: +1-(646)-509-1893, E:
SOURCE: Rosetta Genomics Ltd
/CONTACT: Contact: Media & Investors, Ron Kamienchick, T:
+1-(646)-509-1893, E: firstname.lastname@example.org/
CO: Rosetta Genomics Ltd
ST: North America, Israel
IN: FIN BIO HEA MTC
-- UKM005B --
1217 12/29/2008 08:30 EST http://www.prnewswire.com
Source: Ceresoli G, Zucali P, Favaretto A, et al. Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 2006; 24: 1443-1448.